ZYME logo

ZYME
Zymeworks Inc

2,600
Mkt Cap
$1.8B
Volume
71,946.00
52W High
$28.49
52W Low
$9.03
PE Ratio
-22.41
ZYME Fundamentals
Price
$24.64
Prev Close
$24.18
Open
$24.27
50D MA
$23.50
Beta
0.94
Avg. Volume
537,880.72
EPS (Annual)
-$1.08
P/B
6.77
Rev/Employee
$401,382.58
$1,775.10
Loading...
Loading...
News
all
press releases
Zymeworks Inc. (NASDAQ:ZYME) Given Consensus Rating of "Moderate Buy" by Brokerages
Shares of Zymeworks Inc. (NASDAQ:ZYME - Get Free Report) have earned an average recommendation of "Moderate Buy" from the thirteen research firms that are presently covering the firm, MarketBeat...
MarketBeat·1d ago
News Placeholder
More News
News Placeholder
Assenagon Asset Management S.A. Sells 679,400 Shares of Zymeworks Inc. $ZYME
Assenagon Asset Management S.A. reduced its stake in Zymeworks Inc. (NASDAQ:ZYME - Free Report) by 51.2% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 647,374 shares of the company's stock after selling 679,400 share...
MarketBeat·3d ago
News Placeholder
Zymeworks (NASDAQ:ZYME) Trading Up 9.7% - What's Next?
Zymeworks (NASDAQ:ZYME) Shares Up 9.7% - Still a Buy...
MarketBeat·20d ago
News Placeholder
Zymeworks (NASDAQ:ZYME) Price Target Raised to $46.00
HC Wainwright lifted their price target on shares of Zymeworks from $32.00 to $46.00 and gave the stock a "buy" rating in a research report on Friday...
MarketBeat·24d ago
News Placeholder
Zymeworks (NASDAQ:ZYME) Trading 2.8% Higher on Analyst Upgrade
Zymeworks (NASDAQ:ZYME) Trading Up 2.8% on Analyst Upgrade...
MarketBeat·27d ago
News Placeholder
Zymeworks (NASDAQ:ZYME) Price Target Raised to $47.00
Stifel Nicolaus increased their price target on Zymeworks from $40.00 to $47.00 and gave the company a "buy" rating in a research note on Tuesday...
MarketBeat·27d ago
News Placeholder
Leerink Partners Increases Zymeworks (NASDAQ:ZYME) Price Target to $58.00
Leerink Partners boosted their price objective on Zymeworks from $52.00 to $58.00 and gave the stock an "outperform" rating in a research note on Tuesday...
MarketBeat·27d ago
News Placeholder
Zymeworks Q4 Earnings Call Highlights
Zymeworks (NASDAQ:ZYME) executives used the company's fourth-quarter 2025 results call to highlight updated clinical data for its partnered HER2 antibody zanidatamab, outline a new royalty-backed...
MarketBeat·28d ago
News Placeholder
Zymeworks Inc. (ZYME) Reports Q4 Loss, Lags Revenue Estimates
Zymeworks (ZYME) delivered earnings and revenue surprises of -58.64% and -88.23%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·28d ago
News Placeholder
Zymeworks (NASDAQ:ZYME) Releases Earnings Results, Misses Estimates By $0.20 EPS
Zymeworks (NASDAQ:ZYME - Get Free Report) posted its quarterly earnings data on Monday. The company reported ($0.55) EPS for the quarter, missing analysts' consensus estimates of ($0.35) by ($0.20...
MarketBeat·28d ago
<
1
2
...
>

Latest ZYME News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.